Physician profile
Mark K Kosinski
NPI 1518304054
$3,575.33
in general payments reported to CMS, 2019-2025
8 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $17.27 · 2021: $82.84 · 2022: $48.97 · 2023: $1,180 · 2024: $1,358 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,789 · Food and Beverage: $944 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,789.37 |
| Food and Beverage | $943.68 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,984.44 | 2019-2024 | Mitraclip, Aveir |
| Edwards Lifesciences Corporation | $1,171.05 | 2019-2025 | Pascal, Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Heartflow, INC. | $220.21 | 2023 | Ffrct |
| Lantheus Medical Imaging, INC. | $76.71 | 2021-2022 | |
| Amgen INC. | $35.52 | 2023-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $32.30 | 2025 | Wainua |
| Boston Scientific Corporation | $30.82 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kosinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.